IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company, today announced that Dr. Corinne Le Goff, the company's president and chief executive officer, has issued the following letter to
Fiscal 2023 First Quarter Outlook
For the first quarter of fiscal 2023, the company expects:
Net sales to be around flat to fiscal first quarter 2022 level
Outlook
Everi today initiated full year 2023 guidance for net income of $88 million to $100 million, Adjusted EBITDA of $384 million to $396 million and Free Cash Flow
Full Year 2023 Outlook -- a 52-week Year (comparisons to full year 2022 -- a 53-week year)
Total sales of approximately $88 – $90 billion
Comparable sales expected to be flat to
Financial Guidance
On a pro forma basis, the company exited fourth quarter 2022 at an annualized revenue of approximately $450 million for its remaining business. Management is expecting 2023
2023 Financial Outlook: Revenue Growth:The company expects revenue growth of at least 100% in 2023 Gross Margin: The company expects to reach positive gross margin by the fourth quarter Cash, Cash Equivalents and